ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 222 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $677,849 | -25.1% | 19,014 | -3.1% | 0.00% | -50.0% |
| Q2 2023 | $904,748 | +51.6% | 19,613 | +31.7% | 0.00% | +100.0% |
| Q1 2023 | $596,969 | -9.5% | 14,887 | +4.6% | 0.00% | 0.0% |
| Q4 2022 | $659,368 | +38.2% | 14,232 | +23.5% | 0.00% | 0.0% |
| Q3 2022 | $477,000 | +4.6% | 11,522 | +50.8% | 0.00% | 0.0% |
| Q2 2022 | $456,000 | -18.4% | 7,639 | -0.8% | 0.00% | 0.0% |
| Q1 2022 | $559,000 | +4.1% | 7,704 | +20.6% | 0.00% | 0.0% |
| Q4 2021 | $537,000 | -6.6% | 6,386 | +0.1% | 0.00% | 0.0% |
| Q3 2021 | $575,000 | -2.5% | 6,379 | +3.2% | 0.00% | 0.0% |
| Q2 2021 | $590,000 | -20.4% | 6,184 | -5.0% | 0.00% | 0.0% |
| Q1 2021 | $741,000 | -12.4% | 6,507 | +6.4% | 0.00% | -50.0% |
| Q4 2020 | $846,000 | +95.8% | 6,116 | +16.4% | 0.00% | +100.0% |
| Q3 2020 | $432,000 | +20.0% | 5,253 | +14.2% | 0.00% | 0.0% |
| Q2 2020 | $360,000 | – | 4,599 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |